Ongoing Clinical Studies Clause Samples

Ongoing Clinical Studies. The Termination Party will responsibly wind-down, in accordance with accepted biopharmaceutical industry norms and ethical practices, any on-going clinical studies for which it has responsibility hereunder in which patient dosing has commenced, and Amgen will be responsible for any costs and expenses reasonably associated with or actually incurred with such wind-down.

Ongoing Clinical Studies. The Parties acknowledge and agree that (i) PEI shall be responsible for continuing to manage, and shall use Commercially Reasonable Efforts to complete, the Ongoing Clinical Studies in accordance with the Development Plan; and (ii) MERRIMACK shall bear the Development Costs associated with the conduct of the Ongoing Clinical Studies incurred after the Effective Date in accordance with Section 4.1(d).

Ongoing Clinical Studies the Parties will collaborate to identify and prioritize the transfer of the working study management files for study A4991014 and such other documents and data related to such study as may not have been specifically identified in this Schedule B but the transfer of which nevertheless would facilitate a smooth transition of such trial. In addition, the Parties will meet during the first *** months following the Effective Date at the request of either Transition Coordinator, to discuss such other exchanges of information or steps as shall ensure a smooth transition of such trial.

Ongoing Clinical Studies. No later than 15 Business Days after the effective date of termination, Arrowhead will submit to Sarepta a written notice specifying with respect to all Clinical Trials of the Terminated Products [***] being conducted by or on behalf of Sarepta or its Affiliates as of the effective date of termination, (a) such Clinical Trials that are to be terminated and (b) such Clinical Trials that are to be transferred to Arrowhead or its designee. For any such Clinical Trials identified by Arrowhead in its written notice to be terminated, Sarepta will wind-down such Clinical Trials, at Sarepta’s cost. For any such Clinical Trials identified by Arrowhead in its written notice to be transferred, Sarepta will transfer control to Arrowhead or its designee of such Clinical Trials and will continue to conduct such Clinical Trials after the effective date of termination, at Arrowhead’s cost, for [***] (or such longer period as either Party may reasonably request and is agreed by the other Party) to enable such transfer to be completed to Arrowhead or its designee without interruption of any such Clinical Trials. In no event will Sarepta be required to enroll patients in any such Clinical Trial except as may be otherwise agreed by the Parties or as is reasonably necessary to protect patients.

Ongoing Clinical Studies. Subject to Clause 4.8, Oncolytics shall be responsible for and shall use its Commercially Reasonable Efforts to undertake the Ongoing Clinical Studies in accordance with the relevant protocols.

Ongoing Clinical Studies. If Moderna is conducting (or having conducted on its behalf) any on-going clinical studies for which it has responsibility hereunder in which patient dosing has commenced, Moderna shall either (a) continue to conduct such clinical studies, or (b) responsibly wind-down, in accordance with accepted biopharmaceutical industry norms and ethical practices, and in the case of (a) and (b) Moderna will be responsible for any costs associated therewith.

Ongoing Clinical Studies. The Parties will responsibly wind-down, in accordance with accepted biopharmaceutical industry norms and ethical practices, any on-going clinical studies terminated Product Directed To a terminated Target for which they respectively have responsibility hereunder in which patient dosing has commenced, and the terminating Party will be responsible for any costs associated with such wind-down or transition.

Ongoing Clinical Studies. If at the time of such termination, any Clinical Studies for the Licensed Products are being conducted by or on behalf of Clementia, then, at Blueprint’s election, subject to patient safety and well-being on a Clinical Study-by-Clinical Study basis: (i) Clementia will, and will cause its Affiliates and Sublicensees to, [***], and (ii) Clementia will, and will cause its Affiliates and Sublicensees to, [***]. Clementia will accommodate Blueprint’s reasonable requests to participate in communications with FDA regarding any such Clinical Studies for the Licensed Products, including attending meetings and reviewing minutes of any meetings, material telephone conferences or material discussions with FDA, in each case, solely with respect to applicable Licensed Product and to the extent permitted by FDA.

Ongoing Clinical Studies. R096769-PRE-1005—A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Assessing the Pharmacodynamic Effects of Dapoxetine Concomitantly Administered in Subjects Taking Terazosin R096769PRE3008—A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor; COUPLE: COncomitant Use of PriLigy in Men Treated for Erectile Dysfunction R096769-PRE-4001—A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care; The PAUSE Study (Premature Ejaculation—Actual Use Safety and Effectiveness Study) R096769PRE4005—PRILIGY Usage Patterns in Selected Populations [*] [*] [*]